Biotech Values

[oc631]

But, VRUS continues to report good news with RG7128 and I don't think the next read on data will be until 2012 when Phase 3 results should be out.

There's still quite a few 2B data releases for RG7128 this year. In the Fall they will release the SVR data for the 12 week Propel study and the 24 week Jump-C study. The SOC treatment failure arm from both studies is still enrolling.

If Roche gives up on INFORM, and lets the market know they have, this could be a chance to get in at a lower price.